GlassScriptPhysician profile
Phillip Eskander
NPI 1649650185
$1,414.71
in general payments reported to CMS, 2019-2025
19 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $78.75 · 2021: $175 · 2022: $102 · 2023: $247 · 2024: $380 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $244.87 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $221.95 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.99 | 2019-2024 | Jardiance |
| Pfizer INC. | $130.54 | 2019-2025 | |
| Novo Nordisk INC | $103.98 | 2019-2025 | Ozempic, Rybelsus |
| Melinta Therapeutics, LLC | $100.76 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $97.56 | 2021-2024 | Dificid, Zerbaxa, Recarbrio |
| Boston Scientific Corporation | $77.41 | 2021-2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $57.19 | 2020-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.81 | 2019-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $26.21 | 2019-2024 | Farxiga |
| Alexion Pharmaceuticals, INC. | $25.48 | 2024 | Ultomiris |
| Gilead Sciences, INC. | $24.74 | 2021-2023 | Veklury |
| Csl Behring | $21.63 | 2025 | Kcentra |
| Jazz Pharmaceuticals INC. | $21.60 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $21.39 | 2025 | Eliquis |
| Neurelis, INC. | $17.12 | 2024 | Valtoco |
| Alnylam Pharmaceuticals INC. | $15.99 | 2024 | Givlaari |
| Allergan, INC. | $13.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Eskander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.